Introduction {#s1}
============

The effects of antipsychotic medications in schizophrenia are mediated by their interactions with several receptors expressed in the brain. Currently, the dopamine D2 and the serotonin 2A receptor are assumed to be representative target receptors of antipsychotic drugs. The serotonin 1A receptor (5-HT1AR) is another important receptor, since it has been implicated in both schizophrenia pathogenesis and antipsychotic mechanisms of action. 5-HT1AR is expressed in various sites throughout the brain such as the hippocampus ([@CIT0005]; [@CIT0004]; [@CIT0055]), amygdala, and hypothalamus. A postmortem study including patients with schizophrenia demonstrated elevated 5-HT1AR density in the cortex of the frontal lobe ([@CIT0023]; [@CIT0008]; [@CIT0048]; [@CIT0052]). This might be explained as an effect of serotonergic hypo-activation and glutamatergic hypo-transmission in this region ([@CIT0059]; [@CIT0043]). In addition, second-generation antipsychotics, including aripiprazole, bifeprunox, clozapine, lurasidone, perospirone, quetiapine, and ziprasidone, are hypothesized to exhibit partial agonistic actions on the 5-HT1AR, and molecules directly targeting the 5-HT1AR ameliorate psychiatric symptoms ([@CIT0029]; [@CIT0045]; [@CIT0042]; [@CIT0019]; [@CIT0037]). Furthermore, adjunctive therapy with anxiolytic agents exerting a partial agonistic action on the 5-HT1AR, such as buspirone and tandospirone, is known to improve psychiatric symptoms in schizophrenic patients ([@CIT0033]). Based on these observations, the action of antipsychotics on the 5-HT1AR is supposed to play an important role in the treatment of psychiatric disorders.

The HTR1A gene encoding 5-HT1AR, mapped on chromosome 5q11.2--13, is an intronless gene approximately 2200bp in size, including an approximately 1200-bp coding sequence known to code for 422 amino acids (<http://www.ncbi.nlm.nih.gov/nuccore>). A number of single nucleotide polymorphisms (SNPs) have been identified for HTR1A; a particularly important SNP is rs6295 (C-1019G), which is located in the promoter region and is known to be a functional polymorphism that regulates HTR1A transcription and region-specific modification of HTR1A expression ([@CIT0060]; [@CIT0036]; [@CIT0002]). Thus, pharmacogenetic candidate gene studies were mainly focused on rs6295, and they investigated the relationship between psychiatric drug efficacy in mental disorders and rs6295, with the aim of developing personalized treatments. Several meta-analyses investigated data from studies focused on antidepressant efficacy and the rs6295 polymorphism, but none documented a statistically significant relationship on all populations or on Caucasian/Asian populations ([@CIT0030]; [@CIT0061]; [@CIT0044]). Previous studies identified an association between the rs6295 polymorphism and symptomatic improvement in schizophrenia during treatment with antipsychotics, taking into consideration overall improvement of symptoms ([@CIT0047]), amelioration of negative symptoms ([@CIT0047]; [@CIT0058]; [@CIT0041]), and improved attention ([@CIT0049]). On the other hand, negative findings exist ([@CIT0027]; [@CIT0011]; [@CIT0051]; [@CIT0050]); thus, no clear conclusion can be traced about the effect of this SNP on antipsychotic efficacy. Other HTR1A gene polymorphisms (in particular rs878567 and rs1423691) were investigated in regard to antipsychotic response, even if no functional effect is known for them. Some studies suggested that they may be associated with antipsychotic efficacy ([@CIT0011]; [@CIT0022]; [@CIT0017]; [@CIT0050]).

However, the results obtained to date have not been comprehensively assessed in a meta-analysis. Thus, the present meta-analysis aimed to analyze the cumulative knowledge provided by candidate gene studies focused on the association between HTR1A gene polymorphisms and antipsychotic efficacy in schizophrenia.

Methods {#s2}
=======

This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines ([@CIT0040]).

Search {#s3}
------

We conducted a literature search using PubMed, Web of Science, and Google scholar to identify articles published in English until August 6, 2015. Search queries used were combinations of the following phrases: "schizophrenia or psychosis," "serotonin 1A receptor or 5-HT 1A, HTR1A," "antipsychotics or antipsychotic agents," "response or efficacy," and "gene or polymorphism." In this search, the generic name of each antipsychotic was also used in place of "antipsychotics or antipsychotic agents."

Furthermore, we also manually searched related journals published in English to complement the electronic search. Two independent investigators (Y.T., Y.K.) conducted the literature search.

Inclusion Criteria, Data Extraction, and Outcomes {#s4}
-------------------------------------------------

The following inclusion criteria were applied to select includible studies: (1) They investigated the association between HTR1A polymorphisms and antipsychotic clinical efficacy; (2) The majority of patients had a diagnosis of schizophrenia or schizoaffective disorder based on DSM or ICD criteria (not applicable to patients with first psychotic episode); (3) Drug response was assessed using a standardized rating scale, such as the Positive and Negative Syndrome Scale or the Clinical Global Impression, at baseline and follow-up evaluations; (4) Genotype distribution was in Hardy--Weinberg equilibrium; (5) The study was conducted using the candidate gene approach; (6) The study was published in English and in a peer-reviewed journal; and (7) The study was based on an independent sample (nonoverlapping with other studies). When outcome data were not available in the article, we requested data from the author or we extracted the data from the published figures by the GSYS 2.4 program (Japan Charged-Particle Nuclear Reaction Data Group, <http://www.jcprg.org/gsys/2.4/index-j.html>, Sapporo, Japan). Based on the data obtained from articles that met the above criteria, we selected HTR1A SNPs with at least 3 includible studies. Two authors (Y.T. and Y.K.) independently extracted and checked the data. Any disagreement was resolved by discussion until consensus was reached.

The purposes of the present meta-analysis were to identify possible associations between HTR1A SNPs and baseline to endpoint changes in: overall symptoms, positive symptoms, negative symptoms.

Data Analysis {#s5}
-------------

Data were analyzed using a random-effects model as defined by [@CIT0014], because clinical heterogeneity among the populations and interventions included was expected. The standardized mean difference (SMD) and its 95% CI were calculated for continuous outcomes. Missing SDs were imputed according to the method described in Section 16.1.3 of the Cochrane Handbook for Systematic Reviews of Interventions ([@CIT0054]). Study heterogeneity was measured using the chi-squared and I-squared statistics, with chi-squared values of *P* \< .05 and I^2^ values of \>50% indicating relevant heterogeneity ([@CIT0024]). In addition to the main analysis, we performed a subgroup analysis defined a priory by race, that is, Asians vs Caucasians.

Furthermore, we performed a meta-regression using age (mean age for each sample), sex (percentage of males in each study), and study duration as the moderator variables. Publication bias was assessed by constructing funnel plots and conducting an Egger's test ([@CIT0018]).

Data were analyzed using Review Manager 5.3.5 (Cochrane Informatics & Knowledge Management Department, <http://tech.cochrane.org/revman>). Stata/IC 14.0 (Stata Corporation, College Station, TX, USA) was used to perform the Egger's test and meta-regression analyses.

Results {#s6}
=======

Included Studies {#s7}
----------------

The electronic search yielded a total of 948 potential studies. In addition, we found 5 studies when conducting the manual search. Among the 953 identified hits, 850 articles were found to be duplicated between the databases. Of the 103 unique studies, we excluded 84 articles based on title and abstract reviews. Based on full-text inspection, we excluded 9 other references for the following reasons: the HTR1A polymorphism investigated in the sample was not in Hardy-Weinberg equilibrium (2 articles: [@CIT0007] and [@CIT0041]); all the investigated samples had the same genotype (1 article: [@CIT0038]); therapeutic response was not evaluated (3 articles: [@CIT0031]; [@CIT0021]; [@CIT0053]); the study did not include a polymorphism investigated by at least 2 other articles (2 articles: [@CIT0035]; [@CIT0057]); overlapping samples (1 article: [@CIT0010]).

Ultimately, 10 studies including 1281 patients were included in the present meta-analysis ([@CIT0047]; [@CIT0027]; [@CIT0058]; [@CIT0041]; [@CIT0049]; [@CIT0011]; [@CIT0022]; [@CIT0017]; [@CIT0051]; [@CIT0050]). Three HTR1A polymorphisms were included in the analysis (rs6295 investigated by 10 studies, rs878567 by 4 studies, and rs1423691 by 3 studies). [Figure 1](#F1){ref-type="fig"} shows the flowchart of study selection and inclusion. [Table 1](#T1){ref-type="table"} summarizes the characteristics of the included studies. Each study included 30 to 398 patients (median: 98) with a mean age of 32.4 years and a study duration of 4 weeks to 3 months. Male patients constituted 53.9% of the sample population, with Asians, Caucasians, and South Indians accounting for 53.3%, 17.7%, and 29.0%, respectively. Eight studies included only patients who had been diagnosed with schizophrenia; 3 of these studies were conducted in patients experiencing first-episode schizophrenia. Three studies used a single antipsychotic agent; in 2 of these studies that agent was risperidone. Eight studies used the Positive and Negative Syndrome Scale score as a parameter for assessing psychiatric symptoms, while the others used the Clinical Global Impression-I, SAPS, or SANS score. In all studies, genotype distributions of rs6295, rs878567, and rs1423691 were in Hardy--Weinberg equilibrium. No subgroup analysis or meta-regression was performed for polymorphisms other than rs6295, due to the limited number of studies evaluating these polymorphisms.

###### 

Description of the Included Studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                 **Sample Size (male/female**)   **Country**                         **Ethnicity**   **Age**\   **Setting**            **Diagnostic Criteria**                            **Patient Type**                                   **Medication**                                                **Duration of Treatment**                       **Outcome Measure**         **HTR1A SNP**
                                                                                                                **(SD)**                                                                                                                                                                                                                                                                          
  ------------------------- ------------------------------- ----------------------------------- --------------- ---------- ---------------------- -------------------------------------------------- -------------------------------------------------- ------------------------------------------------------------- ----------------------------------------------- --------------------------- -----------------------------------------
  Crisafulli et al., 2012   221\                            Korea                               Asian           38.01\     In-patients            DSM-IV                                             Not any particular restriction                     RIS, OLZ, QEP, AMI and others (All APDs are not identified)   37.64±1S6.76 days from admission to discharge   PANSS                       rs10042486, rs6295, rs878567, rs1423691
                            (126/95)                                                                            (12.67)                                                                                                                                                                                                                                                                           

  Drago et al., 2013        96\                             German, Yugoslavia, Turkey, Other   Caucasian       34.28\     In-patients            DSM-IV                                             Acute                                              HPD                                                           4W                                              PANSS                       rs6295, rs878567, rs1423691, rs10085024
                            (51/45)                                                                             (11.29)                                                                                                                                                                                                                                                                           

  Gupta et al., 2012        371\                            India                               South Indian    29.63\     In and out- patients   DSM-IV                                             Most of them are of chronic patients               RIS, OLZ, CLZ, ZIP, QEP, ARI, AMI                             3M                                              CGI-I                       rs6295, rs34118353, rs878567, rs1423691
                            (224/147)                                                                           (8.63)                                                                                                                                                                                                                                                                            

  Ikeda et al., 2008        120\                            Japan                               Asian           31.2\      In and out- patients   DSM-IV-TR                                          First-episode, neuroleptic- naïve\                 RIS                                                           8W                                              PANSS                       rs6295
                            (58/62)                                                                             (8.7)                                                                                DUP \< 5 y                                                                                                                                                                                   

  Mossner et al., 2009      68\                             German                              Caucasian       31.7       NR                     ICD-10                                             First-episode                                      RIS, HPD                                                      4W                                              PANSS                       rs6295
                            (44/24)                                                                                                                                                                                                                                                                                                                                                               

  Reynolds et al., 2006     63\                             Spain                               Caucasian       25.1\      In and out- patients   Drug-naive patients with first-episode psychosis   Drug-naive patients with first-episode psychosis   RIS, OLZ, QEP, HPD, ZIP, AMI                                  3M                                              PANSS                       rs6295
                            (45/18)                                                                             (6.5)                                                                                                                                                                                                                                                                             

  Sumiyoshi et al., 2010    30\                             Japan                               Asian           31.6\      Out-patients           DSM-IV-TR                                          Acute                                              OLZ, PER                                                      3M                                              SAPS, SANS                  rs6295
                            (11/19)                                                                             (11.0)                                                                                                                                                                                                                                                                            

  Takekita et al., 2015     100\                            Japan                               Asian           44.1\      In and out- patients   DSM-IV-TR                                          Acute                                              PER, ARI                                                      12W                                             PANSS                       rs1364043, rs878567, rs6295, rs10042486
                            (43/57)                                                                             (16.2)                                                                                                                                                                                                                                                                            

  Tang et al., 2014         82\                             Chinese                             Asian           25.8\      In-patients            DSM-IV                                             First psychotic episode                            Baseline：CPZ, RIS, CLZ, FLU\                                 10W                                             PANSS and PANSS 5 factors   rs6295
                            (45/37)                                                                             (7.1)                                                                                                                                   endpoint：CLZ, CPZ, RIS                                                                                                                   

  Wang et al., 2008         130\                            China                               Asian           30.35\     NR                     DSM-IV                                             \- Not treatment resistance\                       RIS                                                           8W                                              PANSS                       rs6295
                            (43/87)                                                                             (11.33)                                                                              - SGAs-naïve\                                                                                                                                                                                
                                                                                                                                                                                                     - Not APDs administration for 4W                                                                                                                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AMI, amisulpride; APD, antipsychotic drug; ARI, aripiprazole; CGI-I, clinical global impression of improvement; CLZ, clozapine; CPZ, chlorpromazine; DUP, duration of untreated psychosis; FLU, fluphenazine; HPD, haloperidol; NR, not reported; OLZ, olanzapine; PANSS, Positive and Negative Syndrome Scale; PER, perospirone; QEP, quetiapine; RCT, randomized clinical trial; RIS, risperidone; SAPS, scale for assessment of positive symptoms; SANS, scale for the assessment of negative symptoms; SGA, second-generation antipsychotic; SNP, single nucleotide polymorphism; ZIP, ziprasidone.

![Study flow diagram.](ijnppy_pyv125_f0001){#F1}

rs6295 and Antipsychotic Drug Response {#s8}
--------------------------------------

In the total population, no significant correlation was observed between the rs6295 polymorphism and overall symptoms change from baseline to endpoint in the comparison between CC and G carriers (9 studies, SMD = 0.08, Cl = -0.09 to 0.25, *P*=.37), the comparison between C and GG carriers (9 studies, SMD = 0.11, CI = -0.06 to 0.27, *P*=.20), or the comparison between the C allele and the G allele (9 studies, SMD = 0.07, CI = -0.04 to 0.17, *P*=.21; [Figure 2](#F2){ref-type="fig"}; [Table 2](#T2){ref-type="table"}). Similarly, no significant correlation was found between the rs6295 polymorphism and positive symptoms change in the comparison CC vs G carriers (9 studies, SMD = 0.02, Cl = -0.12 to 0.16, P=.76), C vs GG carriers (8 studies, SMD = -0.04, CI = -0.26 to 0.18, *P*=.73), or C vs G allele (8 studies, SMD = -0.01, CI = -0.12 to 0.09, *P*=.84; [Figure 3](#F3){ref-type="fig"}; [Table 2](#T2){ref-type="table"}). Similarly, no significant correlation was found between the rs6295 polymorphism and negative symptoms change in the comparison CC vs G carriers (9 studies, SMD = 0.18, Cl = -0.04 to 0.39, *P*=.10) or the comparison C vs GG carriers (8 studies, SMD = 0.13, CI = -0.09 to 0.36, *P*=.24), but a significantly higher improvement in negative symptoms was observed in C allele carriers when comparing C vs G allele (8 studies, SMD =-0.14, CI = 0.01 to 0.28, *P*=.04) ([Figure 4](#F4){ref-type="fig"}; [Table 2](#T2){ref-type="table"}).

###### 

Association between the HTR1A polymorphisms and antipsychotic efficacy

                            N   N      SMD     95 % CI         Test for Overall Effect   Heterogeneity   *P* Value of Egger's Test        
  ------------------------- --- ------ ------- --------------- ------------------------- --------------- --------------------------- ---- ------
  rs6295                                                                                                                                  
  Overall symptoms                                                                                                                        
   CC vs G carriers         9   1226   0.08    -0.09 to 0.25   .37                       0.90            .06                         47   .243
   C carriers vs GG         9   1226   0.11    -0.06 to 0.27   .20                       1.28            .78                         0    .823
   C alleles vs G alleles   9   2452   0.07    -0.04 to 0.17   .21                       1.24            .20                         27   .352
  Positive symptoms                                                                                                                       
   CC vs G carriers         9   894    0.02    -0.12 to 0.16   .76                       0.30            .67                         0    .112
   C carriers vs GG         8   864    -0.04   -0.26 to 0.18   .73                       0.35            .96                         0    .309
   C alleles vs G alleles   8   1728   -0.01   -0.12 to 0.09   .84                       0.20            .87                         0    .26
  Negative symptoms                                                                                                                       
   CC vs G carriers         9   894    0.18    -0.04 to 0.39   .10                       1.62            .03\*                       53   .292
   C carriers vs GG         8   864    0.13    -0.09 to 0.36   .24                       1.17            .55                         0    .727
   C alleles vs G alleles   8   1728   0.14    0.01 to 0.28    .04\*                     2.04            .12                         38   .29
  rs878567                                                                                                                                
  Overall symptoms                                                                                                                        
   CC vs G carriers         4   743    0.02    -0.14 to 0.17   .85                       0.19            .81                         0    .883
   C carriers vs GG         4   743    0.04    -0.27 to 0.35   .79                       0.27            .20                         36   .616
   C alleles vs G alleles   4   1486   0.02    -0.09 to 0.13   .75                       0.33            .89                         0    .626
  Positive symptoms                                                                                                                       
   CC vs G carriers         3   378    -0.05   -0.27 to 0.16   .63                       0.49            .51                         0    .882
   C carriers vs GG         3   378    -0.12   -0.48 to 0.24   .51                       0.66            .79                         0    .658
   C alleles vs G alleles   3   756    -0.06   -0.22 to 0.11   .49                       0.69            .59                         0    .791
  Negative symptoms                                                                                                                       
   CC vs G carriers         3   378    0.09    -0.13 to 0.31   .41                       0.82            .65                         0    .05
   C carriers vs GG         3   378    0.08    -0.51 to 0.68   .78                       0.28            .10                         57   .931
   C alleles vs G alleles   3   756    0.08    -0.09 to 0.24   .38                       0.89            .93                         0    .771
  rs1423691                                                                                                                               
  Overall symptoms                                                                                                                        
   CC vs G carriers         3   666    -0.04   -0.21 to 0.13   .66                       0.43            .69                         0    .774
   C carriers vs GG         3   666    -0.05   -0.46 to 0.36   .80                       0.26            .07                         62   .419
   C alleles vs G alleles   3   1332   0.00    -0.11 to 0.12   .97                       0.04            .86                         0    .825
  Positive symptoms                                                                                                                       
   CC vs G carriers         2   302    0.06    -0.30 to 0.18   .63                       0.48            .44                         0    NA
   C carriers vs GG         2   302    -0.16   -0.55 to 0.23   .42                       0.81            .62                         0    NA
   C alleles vs G alleles   2   604    -0.07   -0.26 to 0.11   .45                       0.76            .49                         0    NA
  Negative symptoms                                                                                                                       
   CC vs G carriers         2   302    0.03    -0.22 to 0.27   .82                       0.22            .98                         0    NA
   C carriers vs GG         2   302    -0.10   -0.77 to 0.56   .76                       0.31            .09                         65   NA
   C alleles vs G alleles   2   604    0.00    -0.18 to 0.19   .98                       0.02            .47                         0    NA

Abbreviations: NA, not applicable; SMD, standardized mean difference.

\*Significant difference (*P* \< .05).

![Forest plot for the association with rs6295 polymorphism (C alleles vs G alleles) and improvement of overall symptoms.](ijnppy_pyv125_f0002){#F2}

![Forest plot for the association with rs6295 polymorphism (C alleles vs G alleles) and improvement of positive symptoms.](ijnppy_pyv125_f0003){#F3}

![Forest plot for the association with rs6295 polymorphism (C alleles vs G alleles) and improvement of negative symptoms.](ijnppy_pyv125_f0004){#F4}

In regard to heterogeneity, a significant inter-study heterogeneity was observed only for negative symptoms data in the comparison between CG and G carriers (*P*=.03, I^2^ = 53%). No significant heterogeneity was detected in any of the other comparisons for rs6295 ([Table 2](#T2){ref-type="table"}).

rs878567 and Antipsychotic Drug Response {#s9}
----------------------------------------

In the total population (4 studies, n=743), none of the comparisons revealed a significant correlation between the rs878567 polymorphism and changes in all 3 types of psychotic symptoms (overall symptoms, positive symptoms, and negative symptoms) ([Table 2](#T2){ref-type="table"}). There was no significant heterogeneity in any of these comparisons.

rs1423691 and Antipsychotic Drug Response {#s10}
-----------------------------------------

In the total population (3 studies, n = 666), none of the comparisons revealed a significant correlation between the rs1423691polymorphism and changes in all 3 types of psychotic symptoms (overall symptoms, positive symptoms, and negative symptoms) ([Table 2](#T2){ref-type="table"}). There was no significant heterogeneity in any of these comparisons.

Subgroup Analysis, Meta-Regression, and Publication Bias {#s11}
--------------------------------------------------------

In the subgroup analyses by race (Caucasian, Asian, and South Indian), no significant correlation was detected between any phenotype (change in overall symptoms, positive symptoms, or negative symptoms) and the rs6295 polymorphism ([supplementary Table 1](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv125/-/DC1)). No significant heterogeneity was found between subgroups ([supplementary Table 1](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv125/-/DC1)).

Meta-regression analysis of the rs6295 polymorphism indicated higher improvement in negative symptoms in G carriers vs CC carriers as the mean age increased (coefficient = -0.04, SE = 0.012, *P*=.02) ([Table 3](#T3){ref-type="table"}). This result may represent a potential source of the significant inter-study heterogeneity detected in the comparison between rs6295 CC and G carriers for negative symptom improvement. However, no impact of other moderator variables on the association between the rs6295 polymorphism and symptom improvement was found ([Table 3](#T3){ref-type="table"}).

###### 

Results of Meta-Regression Analyses for rs6295

                            Moderator Variable   Coefficient   Standard Error   Test for Overall Effect   Heterogeneity
  ------------------------- -------------------- ------------- ---------------- ------------------------- ---------------
  Overall symptoms                                                                                        
   CC vs G carriers         Study duration       0.005         0.039            .90                       53
  Mean age                  -0.028               0.014         .08              33.76                     
  Male ratio                0.009                0.009         .34              51.02                     
   C carriers vs GG         Study duration       0.008         0.027            .77                       0
  Mean age                  -0.015               0.015         .37              0                         
  Male ratio                -0.006               0.009         .56              0                         
   C alleles vs G alleles   Study duration       0.003         0.021            .91                       36.44
  Mean age                  -0.015               0.015         .37              0                         
  Male ratio                0.003                0.006         .62              35.5                      
  Positive symptoms                                                                                       
   CC vs G carriers         Study duration       -0.022        0.030            .49                       0
  Mean age                  -0.026               0.012         .08              0                         
  Male ratio                0.003                0.007         .65              0                         
   C carriers vs GG         Study duration       0.008         0.036            .84                       0
  Mean age                  -0.010               0.021         .65              0                         
  Male ratio                -0.008               0.010         .48              0                         
   C alleles vs G alleles   Study duration       -0.010        0.020            .63                       0
  Mean age                  -0.015               0.010         .17              0                         
  Male ratio                0.000                0.005         .98              0                         
  Negative symptoms                                                                                       
   CC vs G carriers         Study duration       0.031         0.043            .49                       58.11
  Mean age                  -0.040               0.012         .02\*            0                         
  Male ratio                0.009                0.010         .40              57.72                     
   C carriers vs GG         Study duration       -0.001        0.038            .98                       0
  Mean age                  -0.014               0.021         .54              0                         
  Male ratio                -0.002               0.010         .82              0                         
   C alleles vs G alleles   Study duration       0.015         0.027            .60                       45.44
  Mean age                  -0.023               0.010         .06              0                         
  Male ratio                0.004                0.007         .54              45.69                     

\*Significant difference (*P* \< .05).

Visual inspection of funnel-plots for each distribution of the 3 HTR1A polymorphisms revealed no evidence of publication bias ([supplementary Figure 1](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv125/-/DC1)). Egger's test for publication bias did not suggest evidence of publication bias for any of the performed comparisons for the 3 HTR1A polymorphisms ([supplementary Figure 1](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv125/-/DC1); [Table 2](#T2){ref-type="table"}).

Discussion {#s12}
==========

To our knowledge, this is the first meta-analysis investigating the impact of HTR1A polymorphisms (rs6295, rs1423691, rs878567) on the efficacy of antipsychotic medications in patients with schizophrenia. The analyses were performed employing 3 efficacy parameters, that is, improvement in overall symptoms, positive symptoms, and negative symptoms; 10 studies and 1281 patients were included. Our results indicate that the investigated HTR1A polymorphisms are unlikely to impact overall symptom or positive symptom change during antipsychotic treatment. However, the rs6295 polymorphism showed a small effect on negative symptom improvement in the comparison C vs G allele (*P*=.04, SMD = 0.14, CI = 0.01 to 0.28).

5-HT1AR is considered to play an important role in antipsychotic mechanisms of action both directly and through indirect mechanisms ([@CIT0039]; [@CIT0043]). As a "direct" mechanism, some antipsychotic drugs are known to improve psychiatric symptoms via a partial agonistic action exerted on 5-HT1AR ([@CIT0029]; [@CIT0045]; [@CIT0042]; [@CIT0019]; [@CIT0033]; [@CIT0037]). As an "indirect" effect, second-generation antipsychotics are known to indirectly cause dopamine release in the prefrontal cortex via postsynaptic 5-HT1AR and 5-HT1A autoreceptors present in the raphe nucleus ([@CIT0015]; [@CIT0026]; [@CIT0016]; [@CIT0006]; [@CIT0009]; [@CIT0025]). Functional SNPs in the HTR1A gene have a relevant impact on 5-HT1AR level/activity. Particularly, rs6295 in the promoter region of HTR1A is known to be a functional polymorphism ([@CIT0028]; [@CIT0003]). In raphe cells, the C-G change impairs the binding of nuclear proteins (eg, Deaf1) to a palindrome DNA element located at this polymorphism ([@CIT0036]; [@CIT0003]). The rs6295 G allele is associated with a reduced efficiency of Deaf-1 binding, resulting in increased 5-HT1A autoreceptor expression in the raphe nucleus, where serotonin neurons originate ([@CIT0001]). In contrast, 5-HT1AR expression is hypothesized to be decreased on the postsynaptic side, such as in the prefrontal cortex ([@CIT0012]). Consistently, Deaf1 -/- mice show a 50% increase in 5-HT1A RNA in the raphe, but a 30% decrease in the prefrontal cortex, confirming the role of Deaf1 in regulating HTR1A gene expression ([@CIT0013]). Basic study data suggested that lowered postsynaptic 5-HT1AR density may lead to reduced serotonergic signal transduction, which may in turn reduce dopamine release in the prefrontal cortex ([@CIT0056]; [@CIT0006]). These findings are consistent with the results of the present meta-analysis that support the hypothesis of rs6295 selective impact on negative symptoms. However, this result should be interpreted with caution given that the effect was small (SMD = 0.14).

The other polymorphisms investigated by the present meta-analysis, that is, rs878567 and rs1423691, are located in the HTR1A downstream region, and they involve no amino acid substitutions ([@CIT0020]). It has been suggested that the rs878567 polymorphism might be related to mood disorders (particularly major depressive disorder) ([@CIT0034]), methamphetamine-induced psychosis ([@CIT0032]), and attention deficit-hyperactivity disorder ([@CIT0046]) and that rs1423691 may also be associated with attention deficit-hyperactivity disorder ([@CIT0046]). However, there are no reports supporting a functional effect of these polymorphisms, and the present meta-analysis did not reveal significant correlations between these SNPs and clinical responses to antipsychotics. A limited number of studies was available for these 2 polymorphisms, and further data would be helpful in clarifying their role in antipsychotic response.

The limitations of the present meta-analysis should be considered. First, the number of studies included was small, particularly for rs878567 and rs1423691. Second, only candidate gene studies and not genome-wide association studies were included. Third, nongenetic stratification factors may have influenced the results. Indeed, studies using different antipsychotic drugs were included, and 5-HT1AR binding affinity is not the same for all antipsychotics. It was not possible to perform stratified analyses to account for this source of heterogeneity, since the antipsychotic drugs used varied greatly among the studies. Attention should also be paid to other sources of stratification among the included studies, such as ethnicity, diagnosis, and other clinical differences (eg, disease duration), duration of the study, and tools used to assess symptom improvement.

In conclusion, the present meta-analysis indicated that antipsychotic treatment may be more effective in improving negative symptoms in C allele than in G allele carriers of the HTR1A rs6295 polymorphism. This finding is consistent with data obtained from basic research on the importance of 5-HT1AR in antipsychotic mechanisms of action and the role of the HTR1A rs6295 polymorphism in regulating 5-HT1AR expression. However, this finding showed a small effect size, and relatively few studies and patients were included in the present meta-analysis; thus, the result should be confirmed in larger samples possibly including clinically homogeneous patients.
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